February 5, 2025
The growing convergence between clinical research and clinical care—and ways the second Trump administration will be encouraging and supporting movement in that direction—was the topic of the opening keynote presentation made at this week’s Summit for Clinical Ops Executives (SCOPE) in Orlando. It was presented as an informal but informative dialogue between Janice Chang, CEO of TransCelerate…
Explore
February 3, 2025
This year’s SCOPE conference in Orlando kicked off with a keynote address from Janice Chang, CEO, TransCelerate Biopharma, and Mark McClellan, MD, PhD, director, Duke-Margolis Institute for Health Policy, Former Commissioner, FDA. Titled “Fast Forward to 2035: What Success Could Look Like in Converging Clinical Research and Care—And How to Get There”, the duo discussed…
Explore
December 9, 2024
One major challenge facing the clinical research ecosystem is not whether, but how to study drug safety and efficacy in pregnant and breastfeeding populations. A growing number of organizations—including the ICH E21 Expert Working Group (EWG) and TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative—are diligently seeking ethical and responsible solutions to protect these…
Explore
October 10, 2024
The scientific community intended to protect pregnant and breastfeeding populations when it strictly limited their involvement in clinical trials after the thalidomide crisis of the 1950s-1960s. Yet over the past few decades, people have increasingly recognized the real-life challenges posed by the lack of research into the safety of medications used during pregnancy and breastfeeding.…
Explore
August 16, 2024
Patient safety depends partly on sponsor organizations’ compliance with pharmacovigilance (PV) regulatory requirements—even when global variations exist. Helping sponsors interpret and operationalize challenging PV regulations and guidances is the goal of TransCelerate’s Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) initiative. In this third installment of our IGR PV blog series, we will examine the solutions…
Explore
June 26, 2024
History converged with the future at DIA’s 60th-anniversary Global Annual Meeting. The conference’s theme—Charting New Horizons—fit the mood perfectly. The palpable energy and high attendance levels were reminiscent of pre-pandemic times; it felt like we finally put COVID-19 behind us. Still, underlying this return to “normal” was an eagerness not to forget the lessons of…
Explore
June 20, 2024
Diversity, Equity, and Inclusion (DE&I) and drug safety in clinical trials teams may not have established relationships within an organization. Yet, these two areas of focus have more similarities than one might think. In our next installment of our series on our Interpretation of Pharmacovigilance Guidances and Regulations Initiative (IGR PV), we are exploring this…
Explore
March 22, 2024
This year, TransCelerate honored International Women’s Day, and the theme of “inspiring inclusivity” by gathering a panel of distinguished thought leaders within biopharma R&D for a discussion on “Inspiring Inclusion: The Power of Pivotal Moments.” TransCelerate COO Allison Cuff Shimooka moderated the event. Panelists were Esther Krofah (Milken Institute Health), Joni Rutter (NCATS/NIH), Janet Woodcock…
Explore
February 22, 2024
SCOPE 2024 kicked off with 4,000 attendees traveling to Orlando, Florida, for the much-anticipated event. Common themes shared across all sessions include the importance of collaboration, focusing on patients and their caregivers, and avoiding a “one size fits all” approach to designing clinical trials. Read on for the highlights from TransCelerate’s seven sessions. The conference…
Explore
December 5, 2023
For the second installment of our Interpretation of Pharmacovigilance Guidances & Regulations (IGR PV) Initiative blog series, we will take a deep dive into the initiative and its goals. Established in 2018, this initiative germinated when it became apparent that some of the regulations issued by global Health Authorities can be unclear and/or challenging for…
Explore
